BioMarin Pharmaceutical Inc. filed a Form 8-K on September 14, 2026, disclosing the appointment of Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 10, 2026.

Key Highlights

  • Board expanded: BioMarin increased the size of its Board from ten to eleven members.
  • New director: Robert Plenge, M.D., Ph.D., was appointed to the Board effective September 10, 2026.
  • Committee assignment: Dr. Plenge was also appointed to the Science and Technology Committee of the Board.
  • RSU grant: Dr. Plenge received a restricted stock unit grant valued at $400,000 under the Company's 2017 Equity Incentive Plan, as amended.
  • Vesting schedule: The RSU grant will vest on the date immediately prior to the Company's next regular annual meeting of stockholders.
  • Independent director: Dr. Plenge was not selected pursuant to any arrangement or understanding with any person, according to the filing.

BioMarin Discloses Board Expansion and Plenge Appointment Details

According to the Form 8-K filed with the Securities and Exchange Commission, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) expanded its Board of Directors from ten to eleven members on September 10, 2026, and simultaneously appointed Robert Plenge, M.D., Ph.D., to fill the new seat. The filing states that Dr. Plenge was also named to the Board's Science and Technology Committee on the same date.

The filing discloses that, as an independent non-employee director, Dr. Plenge will receive standard director fees and committee retainer fees as described under the "Director Compensation" section of the Company's definitive proxy statement on Schedule 14A, filed with the SEC on April 21, 2026. In connection with his appointment, Dr. Plenge received a restricted stock unit grant valued at $400,000 under the Company's 2017 Equity Incentive Plan, as amended. The filing describes this as "a pro rata share of the 2026 annual award for non-employee directors" and states it is "consistent with Company policy." The RSU grant will vest on the date immediately prior to the Company's next regular annual meeting of stockholders, the same vesting date that applies to the 2026 annual award for all other non-employee directors.

The Company also disclosed its intention to enter into an indemnification agreement with Dr. Plenge in the same form as its standard indemnification agreement with other directors, referencing Exhibit 10.1 to its Form 8-K filed with the SEC on December 19, 2016. The filing states that Dr. Plenge "has not engaged in any transaction that would be reportable as a related party transaction under Item 404(a) of Regulation S-K." The report was signed by G. Eric Davis, Executive Vice President and Chief Legal Officer.

What Was Disclosed

BioMarin's September 14, 2026 filing reported the expansion of its Board to eleven members and the appointment of Robert Plenge, M.D., Ph.D., effective September 10, 2026, including his committee assignment, a $400,000 RSU grant, and planned indemnification agreement.